News | Radiation Therapy | September 11, 2019

RadCalc 3D Monte Carlo Calculations for Photons Begins Beta Testing

Beta Testing begins of RadCalc 3Dmc version 7.1.1.0 utilizing Monte Carlo 3D dose volume QA technology

RadCalc 3D Monte Carlo Calculations for Photons Begins Beta Testing

September 11, 2019 — RadCalc version 7.1 with the Monte Carlo 3-D module has been released for beta testing to members of the beta testing team. The Monte Carlo 3D module utilizes technology acquired from the McGill University inventors. This release of RadCalc 3Dmc is the second of three 3D Dose Volume second check quality assurance (QA) packages. The completion of the beta test is anticipated in four weeks. An announcement of the final release date will be provided when available for purchase.

RadCalc 3Dmc utilizes the BeamNRC-based Monte Carlo dose calculation engine, providing independent, fast, easy and accurate 3-D dose volume verification for most commonly used treatment planning systems. The RadCalc 3Dmc beta release is compatible with Varian and Elekta machines. Support for additional radiotherapy treatment machines will be available in the near future.

Monte Carlo is widely recognized as the gold standard dose calculation method. The most challenging clinical cases involving highly heterogeneous structures are analyzed with the highest accuracy and confidence. Flexible implementation options allow users to combine the uncompromised accuracy of a Monte Carlo dose calculation algorithm with the levels of speed and productivity that allow busy radiation departments to meet their workflow needs.

RadCalc 3Dmc includes RadCalc AIR (Automated Import & Report) providing a fully automated process with percent difference, dose volume histogram (DVH), Gamma, and Distance to Agreement analysis tools. RadCalc 3Dmc’s fully automated process immediately alerts users to plans that fail to pass pre-set criteria.

RadCalc 3Dmc automatically checks whether DVH objectives are met for critical structures using both the treatment planning system (TPS) and RadCalc 3Dmc dose. Any number of DVH protocols can be loaded and be compared to one another from one analysis screen within RadCalc 3Dmc. Analysis reports are automatically attached to a verified plan and sent to a workstation via email or to a directory of choice on the server.

RadCalc 3Dmc is not yet available for sale in the United States. 

For more information: www.lap-laser.com

Related Content

Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.
Proton therapy has evolved, and future predictions include smaller systems, more sophisticated proton dosimetry and devices that manipulate the proton beam
Feature | Proton Therapy | July 06, 2020 | By Minesh Mehta, M.D.
The field of proton...
Researchers reviewed results of prostate biopsies on over 3,400 men who had targets identified on prostate MRI and found that the positive predictive value of the test for prostate cancer was highly variable at different sites
News | Prostate Cancer | July 01, 2020
July 1, 2020 — Prostate MRI is an emerging technology used to identify and guide treatment for...
Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

News | Pediatric Imaging | June 29, 2020
June 29, 2020 — A type of smart magnetic r...
Case abstraction study period was from 10 March to 7 April 2020. Follow-up of abstracted cases was until 7 May 2020.

Case abstraction study period was from 10 March to 7 April 2020. Follow-up of abstracted cases was until 7 May 2020. Courtesy of Nature Medicine

News | Coronavirus (COVID-19) | June 25, 2020
June 25, 2020 — The characterization of COVID-19
Stephen M. Hahn, M.D., Commissioner of Food and Drugs - Food and Drug Administration

Stephen M. Hahn, M.D., Commissioner of Food and Drugs - Food and Drug Administration

News | Coronavirus (COVID-19) | June 23, 2020
June 23, 2020 — On June 23, 2020, ...
The Global Contrast Injectors Market will grow by $613.47M during 2020-2024, according to Technavio
News | Contrast Media Injectors | June 17, 2020
June 17, 2020 — Technavio has been monitoring the ...